The biggest item this week: FDA told a major 503A pharmacy that a “significant difference” statement picked from a platform menu does not count as a prescriber’s judgment. If your compounded GLP-1 prescriptions go through a template, read item 1 first.
Covers September 11 to 25, 2026. Every item links to the agency document it comes from.
1. FDA: templated “significant difference” statements do not support compounded GLP-1s
On September 18, 2026, FDA issued a warning letter to Empower Clinic Services, LLC dba Empower Pharmacy (MARCS-CMS 738238). FDA found that three tirzepatide/niacinamide and semaglutide/cyanocobalamin products were essentially copies of approved drugs.
The letter says prescriber determinations of “significant difference” appeared “repeated verbatim across many records.” It names “third-party technology platforms that provide prescribers with pre-selected menu options for choosing a statement of significant difference” as a practice that calls the individualized nature of those determinations into question. The letter also cites sterile processing and quality control deficiencies.
What to do: if a compounded GLP-1 order in your clinic carries a stock sentence, the prescriber needs to document the actual patient-specific reason. What changed after the shortage ended.
Source: FDA warning letter 738238
2. Kybella gets new label warnings, and FDA recommends against use outside the chin
On September 15, 2026, FDA approved an added warning for Kybella (deoxycholic acid) about adverse reactions when it is injected outside the submental fat region. FDA “recommends against this unapproved use.” The named events include blurred or reduced vision, muscle and nerve damage, numbness, difficulty walking and difficulty swallowing. FDA counted 129 adverse event cases from use outside the approved site since 2015, and 117 cases of nodules or masses that did not resolve.
What to do: if your menu offers deoxycholic acid for the jawline, arms or body, have your medical director review the protocol and the consent form against the new label. Aesthetics and injectables oversight.
Source: FDA Drug Safety Communication
3. A cord blood cell product is an unapproved drug, says FDA
On September 11, 2026, FDA’s biologics center issued a warning letter to NexCell Scientific Inc (CBER 26-730612) over an umbilical cord blood cell product. FDA found it fails the 21 CFR 1271.10(a) criteria for homologous use and for dependence on living cells, so it is an unapproved new drug and an unlicensed biologic. FDA quoted the company’s website claims about musculoskeletal, liver, neurological and autoimmune conditions.
What to do: a supplier calling a product a “361 HCT/P” does not protect the clinic that administers it. Your own marketing claims are the evidence FDA quotes. Stem cell and exosome marketing.
Source: FDA warning letter 730612
4. CMS opens comment on “any willing pharmacy” contract terms for Part D
On September 24, 2026, CMS published a request for information (FR Doc. 2026-19535). Under section 6223(a) of the Consolidated Appropriations Act, 2026, Part D plans must let any pharmacy that meets standard contract terms join the network. For plan years beginning January 1, 2029, those terms must be “reasonable and relevant” under standards HHS will set. Comments close November 23, 2026.
What to do: if you run a pharmacy that has been kept out of Part D networks, this is the window to describe the terms that did it. Pharmacies and labs.
Source: Federal Register 2026-19535
5. Two online weight-loss products contained hidden sibutramine
On September 15, 2026, FDA warned that LUZE Fit Intensity and Beauty 911, sold online for weight loss, contain undeclared sibutramine. FDA says sibutramine can significantly raise blood pressure or heart rate and poses serious risk for people with heart disease, arrhythmia or stroke history.
What to do: add a line to weight-management intake asking about non-prescription diet products, and check blood pressure before you start a GLP-1. Weight management programs.
Sources: FDA notices for LUZE Fit Intensity and Beauty 911.
What this means for you
Two of this week’s five items turn on documentation. FDA’s GLP-1 letter turns on whether a prescriber’s reasoning is individual, and the Kybella label turns on whether your protocol matches the approved site. Pull one compounded GLP-1 chart and one deoxycholic acid consent form this week and read them as a regulator would. If either would not survive that reading, book a call and we will review it with you.
This is general information, not legal advice. Rules vary by state and change. Confirm your own facts with counsel.